Skip to content

Electroacupuncture versus Transcutaneous Electrical Acupoint Stimulation for Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial

Electroacupuncture versus Transcutaneous Electrical Acupoint Stimulation for Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001261
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-05-18
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Nonspecific Low Back Pain

Interventions

Electroacupuncture Group:Electroacupuncture (EA) Detailed Description: Bilateral Jiaji points (EX-B2) in the lumbar region will be selected. Disposable acupuncture needles (0.30 × 40 mm) will be inse
Transcutaneous Electrical Acupoint Stimulation (TEAS) group:Small, disposable hydrogel electrodes will be attached to the skin surface of the lumbar region and connected to a transcutaneous electrical

Sponsors

Tianjin Binhai New Area Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria (1) Meet the diagnostic criteria for chronic nonspecific low back pain described above; (2) Aged 18 to 65 years (inclusive), with no gender restriction; (3) Low back pain Visual Analogue Scale (VAS) score = 40 mm; (4) The subject has been informed of the study details, signs the informed consent form, and voluntarily agrees to participate in this study.

Exclusion criteria

Exclusion criteria: Exclusion Criteria (1) Presence of specific low back pain indicated by lumbar MRI/CT within 3 months, including spinal tumors (primary or metastatic), vertebral fractures, spinal infection, spinal cord injury, myelitis, ankylosing spondylitis, or clinically significant spinal deformities (spondylolisthesis, spondylolysis, or scoliosis); (2) Clinical signs of cauda equina compression (e.g., saddle area paresthesia, bowel or bladder dysfunction or incontinence, progressive lower limb weakness, etc.); (3) Abnormal heart, liver, or kidney function, or serious general warning signs (fever on most days in the past month; unexplained weight loss of 5 kg or more in the recent period); (4) Presence of widespread pain or radicular signs; (5) Presence of conditions unsuitable for electroacupuncture treatment, such as implanted cardiac pacemaker, bleeding tendency or current use of anticoagulant medications (e.g., warfarin), history of needle phobia, history of lumbar spine surgery (including discectomy, fusion, etc.), or uncontrolled epilepsy; (6) Receipt of any form of acupuncture (including manual acupuncture, electroacupuncture, etc.) for chronic low back pain within the past 1 year; (7) Use of glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications with therapeutic effects on chronic low back pain within the past 4 weeks (patients may be rescreened after a washout period of 5 half-lives); (8) Presence of local skin lesions, infection, dermatitis, or allergy to electrode pad adhesive, making the patient unsuitable for transcutaneous electrical acupoint stimulation; (9) Presence of severe mental illness or cognitive impairment that precludes cooperation with treatment and evaluation; (10) Planned spinal surgery or other interventional procedures (e.g., glucocorticoid injections) during the trial treatment period; (11) Women who are pregnant, lactating, or planning to become pregnant. Note: Patients meeting any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS) for Low Back Pain;

Secondary

MeasureTime frame
Roland-Morris Disability Questionnaire Score (RMDQ);Oswestry Disability Index Score (ODI) ;36-Item Short Form Health Survey Score (SF-36);Fear-Avoidance Beliefs Questionnaire (FABQ);Patient Global Assessment (PGA);Rescue Medication Use;Incidence of adverse events (AEs);Functional near-infrared spectroscopy (fNIRS);

Countries

China

Contacts

Public ContactLianqi Geng

Tianjin Binhai New Area Hospital of Traditional Chinese Medicine

genglianqi@163.com13920956132

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026